Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Abstract
This brief perspective article focuses on the most common errors and pitfalls, as well as the do's and don'ts in drug combination studies, in terms of experimental design, data acquisition, data interpretation, and computerized simulation. The Chou-Talalay method for drug combination is based on the median-effect equation, derived from the mass-action law principle, which is the unified theory that provides the common link between single entity and multiple entities, and first order and higher order dynamics. This general equation encompasses the Michaelis-Menten, Hill, Henderson-Hasselbalch, and Scatchard equations in biochemistry and biophysics. The resulting combination index (CI) theorem of Chou-Talalay offers quantitative definition for additive effect (CI = 1), synergism (CI 1) in drug combinations. This theory also provides algorithms for automated computer simulation for synergism and/or antagonism at any effect and dose level, as shown in the CI plot and isobologram, respectively.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, a consideration of the drug pharmacological synergy by the analysis CI using the isobologram equation of Chou–Talalay [22], suggested that the synergy strongly depends on the drug ratio.”
In the citing paper
“For example, when the Chou-Talalay method is applied to in vivo studies (9, 36), it requires multiple dose levels for each drug, so there will be may groups (for an example, see ref. 37), while in practice, we normally have only four groups, not only to save cost but to focus on the selected drug dose levels.”
From Statistical Assessment of Drug Synergy from In Vivo Combination Studies Using Mouse Tumor Models (2023) · cites this paper as [9]
In the citing paper
“pharmacological ERK inhibition conferred a highly synergistic, >100-fold sensitization to SRC inhibition in CRC240 cells (CI < 1.0 by Chou-Talalay method”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Chou, 2010
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 11×
“The resulting combination index (CI) theorem of Chou-Talalay offers quantitative definition for additive effect (CI = 1), synergism (CI < 1), and antagonism (CI > 1) in drug combinations.”
BackgroundInfluentialSelf-citationChou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163 · cited 10×
“With these parameters [(m)1, (Dm)1 and (m)2, (Dm)2] available, we could determine whether there is synergism or antagonism, quantitatively, by using the CI equation, even for only a single combination data point (1).”
BackgroundMethodInfluentialSelf-citationEnzyme and metabolic inhibitors
Webb, J. L. (1963) · Academic Press eBooks · doi:10.5962/bhl.title.7320 · Cited by 1,514
The search for synergy: a critical review from a response surface perspective.
Greco, W. R., Bravo, G., & Parsons, J. C. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06847-4 · Cited by 1,434
Berenbaum, M. C. (1989) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00026-2 · Cited by 1,414
Die Kinetik der Invertinwirkung
Michaelis, L., & Menten, M. L. (2007) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · Cited by 1,234
Analysis of combined drug effects: a new look at a very old problem
Chou, T.-C., & Talalay, P. (1983) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(83)90490-x · Cited by 619
Self-citationEron, J. J., Benoit, S. L., Jemsek, J., MacArthur, R. D., Santana, J., Quinn, J. B., Kuritzkes, D. R., Fallon, M. A., & Rubin, M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512213332502 · Cited by 531
Chou, T.-C., Motzer, R. J., Tong, Y., & Bosl, G. J. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.20.1517 · Cited by 524
Self-citationCHOU, T.-C., & TALALAY, P. (2005) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1981.tb06218.x · Cited by 419 · cited 1×
“(18)] and only if the effects of both drugs are mutually nonexclusive (1, 10).”
BackgroundSelf-citation
Research works printed but not linked: 5
- Chou, 1991, The median-effect principle and the combination index for quantitation of synergism and antagonism, 61
- Chou, 1989, Dose-effect analysis with microcomputers: quantitation of ED50, ID50, synergism, antagonism, low-dose risk, receptor ligand binding and enzyme kinetics: computer software for the IBM PC series
- Chou, 1997, CalcuSyn for Windows: multiple-drug dose-effect analyzer and manual
- Chou, 2008, Drug combination against xenograft tumors in nude mice: experimental design, execution, and computerized simulation of synergism and antagonism (an abstract for the mini-symposium), Proc Am Assoc Cancer Res, 49, 997
- Chou, 1998, Computerized indexing of drug combinations: prediction of synergism and antagonism of more than two drugs by polygonogram [abstract], FASEB J, 12, 832
Cited by
Tumor targeting via EPR: Strategies to enhance patient responses
Golombek, S. K., May, J.-N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.007 · Cited by 1,262
Analysis of drug combinations: current methodological landscape
Foucquier, J., & Guedj, M. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.149 · Cited by 1,115
Synergy and antagonism in natural product extracts: when 1 + 1 does not equal 2
Caesar, L. K., & Cech, N. B. (2019) · Natural Product Reports · doi:10.1039/c9np00011a · Cited by 881
Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model
Yadav, B., Wennerberg, K., Aittokallio, T., & Tang, J. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.09.001 · Cited by 845
“As pointed out by many others [8 – 10], there is still no standardized guideline on how to choose the optimal reference model.”
BackgroundCombenefit: an interactive platform for the analysis and visualization of drug combinations
Di Veroli, G. Y., Fornari, C., Wang, D., Mollard, S., Bramhall, J. L., Richards, F. M., & Jodrell, D. I. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw230 · Cited by 736
Metadata
- Authors
- Chou, T.-C.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Chou, Ting-Chao
- ORCID
- Chou, Ting-Chao
- Venue
- Cancer Research
- Published
- 2010-01-13
- Volume
- 70
- Issue
- 2
- Pages
- 440-446
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2096439168
- Cited by
- 5,739
- References
- 24
- Citations by year
- 2026: 337 · 2025: 446 · 2024: 494 · 2023: 493 · 2022: 521 · 2021: 564 · 2020: 570 · 2019: 486 · 2018: 417 · 2017: 338 · 2016: 312 · 2015: 256 · 2014: 185 · 2013: 150 · 2012: 87
- FWCI
- 102.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- Chou-Talalay method, combination index, mass action law, isobologram, antagonism, experimental design, data interpretation
- MeSH terms
- Algorithms, Animals, Drug Synergism, Drug Therapy, Combination, Pharmaceutical Preparations, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method. https://app.cochat.ai/papers/10.1158/0008-5472.can-09-1947
- The paper
- Chou, T.-C. (2010). Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method. Cancer Research. https://doi.org/10.1158/0008-5472.can-09-1947
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.